Elixirgen Therapeutics Announces Dosing of First and Second Participants in its COVID-19 Vaccine Phase 1/2 Clinical Trial at Fujita Health University
BALTIMORE, May 25, 2021 — Elixirgen Therapeutics, Inc., a Baltimore-based biotechnology company focused on the discovery and development of therapies for genetic diseases and vaccines, today announced the dosing of the first and second participants in its COVID-19 vaccine Phase 1/2 Clinical Trial in Japan. The vaccine, called EXG-5003, is an intradermally-injected, temperature-controllable, self-replicating RNA […]